Search
Danoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Meplazumab
go.drugbank.com/drugs/DB16465InvestigationalMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Recombinant Bacterial ACE2 Receptors-like Enzyme
go.drugbank.com/drugs/DB15741InvestigationalB38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction. … B38-CAP is structured as a carboxypeptidase and derived from _Paenibacillus sp._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2
Pipamperone
go.drugbank.com/drugs/DB09286InvestigationalIt was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. … Pipamperone is a typical antipsychotic of the _butyrophenone_ family used in the treatment of schizophrenia.
Rufinamide
go.drugbank.com/drugs/DB06201ApprovedClinical trials suggest its efficacy in the treatment of partial seizures. … Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.
CCR5 mAb
go.drugbank.com/drugs/DB05906ExperimentalIt was generated by HGS using the Abgenix XenoMouse technology. … CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
AVI-4020
go.drugbank.com/drugs/DB05873InvestigationalAVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).